Five, seven or ten? No – it’s not a trendy store for juniors… it is a real-life anti-estrogen treatment dilemma facing oncologists and their post-menopausal, ER+, early-stage, breast cancer patients. Standard of care is to take anti-estrogen treatment for at least the first 5 years after diagnosis to help prevent hormone-receptor positive breast cancer recurrences. […]
So what are the experts saying about anti-estrogen therapy for pre-menopausal patients diagnosed with breast cancer? Late last year, three dynamic oncologists from the University of Wisconsin, Madison – Amye Tevaarwerk, MD; Kari Wisinski, MD; and Ruth O’Regan, MD – collaborated to publish a review about the history and current state of anti-estrogen treatment. for […]
From the very beginning of your journey, you are encouraged to focus on yourself and your treatment while fighting early-stage, estrogen receptor positive (ER+) breast cancer. But, the financial burden from out-of-pocket medical expenses can build up and distract you from this focus. You didn’t budget for cancer. No one budgets for cancer. For example, […]
Advancements in breast cancer screening have increased cancer detection in patients previously not considered at risk for disease and have helped diagnose the disease at earlier stages. Breast cancer screening and early detection have been game changers for patients and their healthcare teams. Finding cancer early in patients opens up a variety of treatment options for both the initial and survivorship phases.
Researchers continue to push for progress in all aspects of screening, diagnosis and monitoring disease. Advances in our knowledge of breast cancer biology have led to the development of diagnostic methods that can help to tailor the treatment plan to specific types of breast cancer.